Influenza remains one of the most prevalent respiratory infections worldwide, creating a persistent need for effective prevention and immunization programs. Seasonal outbreaks, the risk of severe complications, and increasing awareness of preventive healthcare continue to support vaccination demand.
The Influenza Vaccines Market was valued at US$7.48 billion in 2021 and is projected to reach US$12.27 billion by 2028, registering a CAGR of 7.4% from 2022 to 2028. Rising vaccination coverage, technological advancements, product approvals, and investments in manufacturing capacity are among the major factors supporting this expansion.
Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00004070
Increasing Focus on Influenza Prevention and Immunization
Influenza can cause substantial healthcare burdens, particularly among infants, children, older adults, and individuals with underlying health conditions. According to the World Health Organization, seasonal influenza is associated with millions of cases of severe illness and hundreds of thousands of respiratory deaths globally each year. These health risks have encouraged governments, healthcare organizations, and pharmaceutical companies to strengthen seasonal vaccination programs.
The COVID-19 pandemic further highlighted the importance of respiratory disease prevention and increased public awareness regarding vaccination. During the 2020 influenza season, influenza vaccine administration in the US increased compared with previous years, reflecting greater interest in protecting against respiratory infections. Expanding public immunization campaigns and increased healthcare expenditure are therefore expected to create sustained opportunities for vaccine manufacturers.
Quadrivalent Vaccines Lead Product Demand
Based on vaccine type, the industry is segmented into quadrivalent and trivalent vaccines. Quadrivalent vaccines accounted for the largest share, representing 88.1% in 2021, and are expected to maintain their leading position during the forecast period.
The strong adoption of quadrivalent formulations is associated with their broader coverage against influenza virus strains. Product approvals, launches, and improvements in vaccine formulations are also encouraging healthcare providers and immunization programs to adopt these products. As manufacturers continue developing vaccines with improved effectiveness and broader protection, the quadrivalent segment is expected to remain a major contributor to overall growth.
By virus type, influenza virus type A held a significant share in 2021 and is anticipated to register a CAGR of 7.6% during the forecast period. The prevalence and broad epidemiological impact of influenza A contribute to sustained demand for vaccines targeting this virus type.
Technological Advancements Strengthen Vaccine Production
Technology represents another important competitive factor. The industry is segmented into egg-based and cell-based technologies. Egg-based vaccines accounted for 78.6% of the share in 2021 because of their established manufacturing infrastructure, extensive clinical experience, and widespread commercial availability.
However, cell-based technologies are gaining attention as manufacturers seek flexible production approaches and improved responsiveness to changing influenza strains. Investments in vaccine research, manufacturing infrastructure, and next-generation technologies are expected to support innovation across the sector.
Route of administration also influences product adoption. Injection remains the dominant delivery method, while nasal spray formulations provide an alternative for eligible populations. The injection segment is anticipated to register a CAGR of 7.8% during the forecast period, supported by widespread clinical use and established vaccination programs.
Government Investments and Strategic Initiatives Create Opportunities
Increasing investments by pharmaceutical companies and governments are strengthening production capacity and supporting long-term supply security. For example, Sanofi announced plans for approximately US$925 million in investment toward a new vaccine manufacturing facility in Toronto, Canada, aimed at increasing antigen and filling capacity for influenza vaccines.
Seqirus also announced plans to invest approximately US$800 million in an Australian vaccine manufacturing center. Such investments demonstrate the growing emphasis on domestic and regional vaccine manufacturing capabilities.
Strategic collaborations and supply agreements are also shaping the competitive environment. GSK entered into an agreement with the Government of Canada covering pandemic and seasonal influenza vaccines, including supplies of Flulaval Tetra and pandemic vaccine doses. These initiatives are expected to strengthen supply networks while supporting preparedness for future influenza outbreaks.
Key players include:
- Sanofi SA
- GSK plc
- CSL Seqirus
- AstraZeneca plc
- Moderna, Inc.
- Viatris Inc.
- Serum Institute of India Pvt. Ltd.
- Hualan Biological Engineering Inc.
- Emergent BioSolutions Inc.
- Mitsubishi Chemical Group Corporation
Regional Growth and Competitive Landscape
North America dominated the industry with a 39.5% share in 2021, supported by established vaccination infrastructure, strong healthcare expenditure, high awareness, and the presence of major vaccine manufacturers. The US is projected to register a CAGR of 7.9% during the forecast period.
Asia Pacific is also emerging as an attractive growth region and is expected to register a CAGR of 7.9%. Growing healthcare investments, expanding immunization programs, rising awareness, and increasing vaccine manufacturing capabilities in countries such as China and India are expected to support regional expansion.
Competition is increasingly centered on product innovation, manufacturing expansion, regulatory approvals, strategic partnerships, and portfolio diversification. Leading companies are investing in improved formulations and production technologies to address evolving influenza strains and changing public health requirements.
Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00004070
Future Outlook
Expanding immunization programs, increasing government and private-sector investments, wider adoption of quadrivalent vaccines, and advances in cell-based production are likely to remain important growth drivers. Continued innovation in vaccine formulations, manufacturing capacity, and delivery approaches will further strengthen the industry’s ability to respond to seasonal influenza and future respiratory disease threats.
Related Report:
1) Drug Discovery Informatics Market Size, Share, and Growth Forecast to 2031
2) Non-Gelatin Empty Capsules Market Size, Trends & Forecast 2031
3) Drug Delivery Devices Contract Manufacturing Market – Size, Share & Forecast by 2034
About Us –
The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.
Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean German Japanese French Chinese Italian Spanish
